The hardware and bandwidth for this mirror is donated by dogado GmbH, the Webhosting and Full Service-Cloud Provider. Check out our Wordpress Tutorial.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]dogado.de.
Creates the optimal (D, U and I) designs for the accelerated life testing with right censoring or interval censoring. It uses generalized linear model (GLM) approach to derive the asymptotic variance-covariance matrix of regression coefficients. The failure time distribution is assumed to follow Weibull distribution with a known shape parameter and log-linear link functions are used to model the relationship between failure time parameters and stress variables. The acceleration model may have multiple stress factors, although most ALTs involve only two or less stress factors. ALTopt package also provides several plotting functions including contour plot, Fraction of Use Space (FUS) plot and Variance Dispersion graphs of Use Space (VDUS) plot. For more details, see Seo and Pan (2015) <doi:10.32614/RJ-2015-029>.
Version: | 0.1.2 |
Depends: | R (≥ 3.0.0) |
Imports: | cubature (≥ 1.0), lattice (≥ 0.20), methods |
Published: | 2019-12-12 |
DOI: | 10.32614/CRAN.package.ALTopt |
Author: | Kangwon Seo [aut, cre], Rong Pan [aut] |
Maintainer: | Kangwon Seo <seoka at missouri.edu> |
License: | GPL-3 |
NeedsCompilation: | no |
In views: | ExperimentalDesign |
CRAN checks: | ALTopt results |
Reference manual: | ALTopt.pdf |
Package source: | ALTopt_0.1.2.tar.gz |
Windows binaries: | r-devel: ALTopt_0.1.2.zip, r-release: ALTopt_0.1.2.zip, r-oldrel: ALTopt_0.1.2.zip |
macOS binaries: | r-release (arm64): ALTopt_0.1.2.tgz, r-oldrel (arm64): ALTopt_0.1.2.tgz, r-release (x86_64): ALTopt_0.1.2.tgz, r-oldrel (x86_64): ALTopt_0.1.2.tgz |
Old sources: | ALTopt archive |
Please use the canonical form https://CRAN.R-project.org/package=ALTopt to link to this page.
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.
Health stats visible at Monitor.